A detailed history of Callan Capital, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Callan Capital, LLC holds 6,562 shares of BMY stock, worth $379,021. This represents 0.02% of its overall portfolio holdings.

Number of Shares
6,562
Holding current value
$379,021
% of portfolio
0.02%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$39.66 - $51.75 $260,248 - $339,583
6,562 New
6,562 $339,000
Q1 2024

Oct 22, 2024

BUY
$47.98 - $54.4 $274,349 - $311,059
5,718 New
5,718 $310,000
Q1 2024

May 03, 2024

BUY
$47.98 - $54.4 $274,349 - $311,059
5,718 New
5,718 $310,000
Q3 2023

Nov 06, 2023

BUY
$57.89 - $64.73 $121,511 - $135,868
2,099 Added 59.8%
5,609 $325,000
Q2 2023

Aug 04, 2023

SELL
$63.71 - $70.74 $4,141 - $4,598
-65 Reduced 1.82%
3,510 $224,000
Q4 2022

Feb 13, 2023

BUY
$68.48 - $81.09 $244,816 - $289,896
3,575 New
3,575 $257,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Callan Capital, LLC Portfolio

Follow Callan Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Callan Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Callan Capital, LLC with notifications on news.